Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Hubert Chen, MD
- Telefonnummer: 8587044660
- E-mail: clinicaltrials@vikingtherapeutics.com
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85741
- Rekruttering
- Viking Clinical Site #2020
-
Kontakt:
- Telefonnummer: 520-333-4515
-
-
California
-
Lake Forest, California, Forenede Stater, 92630
- Rekruttering
- Viking Clinical Site #2015
-
Kontakt:
- Telefonnummer: 714-550-9990
-
-
Florida
-
Ocoee, Florida, Forenede Stater, 34761
- Rekruttering
- Viking Clinical Site #2059
-
Kontakt:
- Telefonnummer: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Viking Clinical Site #2013
-
Kontakt:
- Telefonnummer: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, Forenede Stater, 47714
- Rekruttering
- Viking Clinical Site #2001
-
Kontakt:
- Telefonnummer: 812-477-2760
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Viking Clinical Site #2046
-
Kontakt:
- Telefonnummer: 504-336-2667
-
Valparaiso, Indiana, Forenede Stater, 46383
- Rekruttering
- Viking Clinical Site #2009
-
Kontakt:
- Telefonnummer: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, Forenede Stater, 55423
- Rekruttering
- Viking Clinical Site #2004
-
Kontakt:
- Telefonnummer: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39206
- Rekruttering
- Viking Clinical Site #2029
-
Kontakt:
- Telefonnummer: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, Forenede Stater, 65807
- Rekruttering
- Viking Clinical Site #2028
-
Kontakt:
- Telefonnummer: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87107
- Rekruttering
- Viking Clinical Site #2052
-
Kontakt:
- Telefonnummer: 505-243-1627
-
-
New York
-
Binghamton, New York, Forenede Stater, 13905
- Rekruttering
- Viking Clinical Site #2039
-
Kontakt:
- Telefonnummer: 607-800-5777
-
-
Oregon
-
Medford, Oregon, Forenede Stater, 97504
- Rekruttering
- Viking Clinical Site #2023
-
Kontakt:
- Telefonnummer: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, Forenede Stater, 02818
- Rekruttering
- Viking Clinical Site #2002
-
Kontakt:
- Telefonnummer: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29407
- Rekruttering
- Viking Clinical Site #2044
-
Kontakt:
- Telefonnummer: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, Forenede Stater, 37075
- Rekruttering
- Viking Clinical Site #2030
-
Kontakt:
- Telefonnummer: 504-339-0917
-
-
Texas
-
Abilene, Texas, Forenede Stater, 79606
- Rekruttering
- Viking Clinical Site #2031
-
Kontakt:
- Telefonnummer: 325-400-1150
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Viking Clinical Site #2011
-
Kontakt:
- Telefonnummer: 206-536-3030
-
Spokane, Washington, Forenede Stater, 99218
- Rekruttering
- Viking Clinical Site #2042
-
Kontakt:
- Telefonnummer: 509-505-6227
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
Eksperimentel: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Eksperimentel: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Eksperimentel: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tidsramme: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- VK2735-305
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .